These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26575466)

  • 1. Active Immunotherapy of Cancer.
    Chodon T; Koya RC; Odunsi K
    Immunol Invest; 2015; 44(8):817-36. PubMed ID: 26575466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
    Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
    Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Immunotherapy: Theory and Application.
    Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
    J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
    Huang MA; Krishnadas DK; Lucas KG
    J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 13. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
    Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
    Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
    Marabelle A; Gray J
    Pediatr Blood Cancer; 2015 Aug; 62(8):1317-25. PubMed ID: 25808079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive cell therapy: past, present and future.
    Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
    Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.